Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...